Prof. Hsien-Yuan Lan


Academic Degree(s)





Current Position

  • Professor & Director, Graduate Institute of Biomedical Sciences, China Medical University Medical College, Taichung, Taiwan
  • Chief, Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan


Professional Experience

  • 2007-present, Professor and Director, Graduate Institute of Clinical Medical Science, China Medical University
  • 2016-present, Director, Brain Disease Research Center, China Medical University and Hospital, Taichung, Taiwan

  • 2013-2017,  President, Taiwanese Society of Schizophrenia Research


Education & Training

  • 1980-1987,  Taipei Medical College, Taipei, M.D.
  • 1995-2000,  National Defense Medical College, Taipei, Ph.D.



  • 2012  Laureate Research Award, China Medical University, Taiwan
  • 2013  The 10th National Innovation Award, Taiwan
  • 2014  The 24th Wang-Ming-Ning Award
  • 2014  Ministry of Science and Technology (MOST) Outstanding Research Award
  • 2016  The International of College of Neuropsychopharmacology (CINP) CNS Drug Innovation Award


Research Grants

  • D-amino acid oxidase inhibitor for treatment of behavioral and psychological symptoms in dementia (NSC-101-2325-B-039-009; MOST 105-2325-B-039-005 -)
  • Multidisciplinary study of novel NMDA modulation for neurodegenerative disorder (1/3; 2/3) (MOST 105-2632-B-039-003; MOST 106-2632-B-039-002)
  • Taiwan Clinical Trial Consortium for mental disorders (NSC 102-2325-B-039 -010; MOST 103-2325-B-039 -005; MOST 104-2325-B-039-004; MOST 105-2325-B-039-002; MOST 106-2321-B-039-004 )
  • Benzoate treatment for major depressive disorder (1/3) (MOST 106-2622-B-039-001-CC2)


Committee & Membership

  • 2009-present, Councillor and organizing committee, Asian College of Neuropsychopharmacology
  • 2011-present, Fellow, The International College of Neuropsychopharmacology
  • 2016-present, International Advisory Board, Asian Congress on Schizophrenia Research


Selected Publication

  • Lane HY, Chang YC, Liu YC, Chiu CC, Tsai G. Sarcosine (N-methylglycine) or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Archives of General Psychiatry 2005;62:1196-1204
  • Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Chen PW, Tsai G.  Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biological Psychiatry 2006;60:645-649
  • Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Tsai G. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biological Psychiatry 2008;63:9-12 (selected for the commentary article)
  • Lane HY, Lin C-H, Huang CL, Chang YC, Liau CH, Tsai GE. A Randomized, double-blind, placebo-controlled study of sarcosine (N-methylglycine) and D-serine add-on treatment for chronically stable schizophrenia. International Journal of Neuropsychopharmacology 2010;13:451-460
  • Lane HY, Liu YC, Huang CL, Hsieh CL, Chang YL, Chang L, Chang YC, Chang WH. Prefrontal executive function and D1, D3, 5-HT2A, and 5-HT6 receptors gene variations in healthy participants. Journal of Psychiatry and Neuroscience 2008;33:47-53
  • Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 2013;70:1267-1275
  • Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, Tun R, Huang KH, Chang YC, Lane HY*, Tsai G. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biological Psychiatry 2013; 74:734-741. [*corresponding author] (selected for the commentary article)
  • Lin CH, Chang HT, Chen YJ, Lin CH, Huang CH, Tun R, Tsai, G, Lane HY*: Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals. Molecular Psychiatry 2014;19:636-637  [*corresponding author]
  • Lin CH, Chen PK, Chou LJ, Chang YC, Chen YS, Tsai GE, Lane HY*. Benzoate, a D-amino acid oxidase inhibitor, for treatment of early-phase Alzheimer's disease: a randomized, double-blind, placebo-controlled trial. Biological Psychiatry 2014;75:678-685 [*corresponding author]
  • Lin CH, Lin PP, Lin CY, Lin CH, Huang CH, Huang YJ, Lane HY*. Decreased mRNA expression for the two subunits of system xc-, SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: evidence in support of the hypo-glutamatergic hypothesis of schizophrenia. Journal of Psychiatric Research 2016; 72:58-63 [*corresponding author]